Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.
Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.
Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now